SEC Form 4 · accession 0001415889-17-001079
INNOVUS PHARMACEUTICALS, INC. · INNV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ziad Mirza
Director
Period of report
Jul 1, 2017
Accepted (ET)
Jul 3, 2017 · 6:00 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jul 1, 2017 | A | 26,643 | A | Jul 1, 2017 | Jul 1, 2027 | Common Stock | 26,643 | 1,649,263 | D |
Explanation of responses
- F1Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F2The Reporting Person was granted a Restricted Stock Unit on July 1, 2017 of 53,286 shares, which were fully vested on the date of the grant.
- F3These restricted stock units were granted pursuant to the Issuer's 2016 Equity Incentive Plan.